“靶向药行业研究”的版本间的差异

来自BioHos-生命健康创投百科
跳转至： 导航、 搜索
（以“#史上最全癌症靶向药（2017版） https://mp.weixin.qq.com/s/7mpVHYy4QV8DZZFrU5Nc8w”为内容创建页面）
 
 
（未显示同一用户的5个中间版本）
第1行： 第1行：
 +
 +
[[category:行业研究]]
 +
<div style="max-width:73%;
 +
background-color:#C1FFC1;
 +
border:0px solid #000000;">
 
#史上最全癌症靶向药（2017版）  https://mp.weixin.qq.com/s/7mpVHYy4QV8DZZFrU5Nc8w
 
#史上最全癌症靶向药（2017版）  https://mp.weixin.qq.com/s/7mpVHYy4QV8DZZFrU5Nc8w
 +
#Overview of Targeted Therapies for Cancer - My Cancer Genome  https://www.mycancergenome.org/content/molecular-medicine/overview-of-targeted-therapies-for-cancer
 +
#New FDA Approved Drugs for 2017 | CenterWatch  http://www.centerwatch.com/drug-information/fda-approved-drugs/
 +
#A to Z List of Cancer Drugs - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs
 +
===淋巴瘤===
 +
#Ibrutinib（依鲁替尼），靶点BTK，Ibrutinib (PCI-32765) | BTK 抑制剂  http://www.selleck.cn/products/pci-32765.html Ibrutinib - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/ibrutinib
 +
#Ibritumomab tiuxetan（替伊莫单抗），靶点CD20，抗癌新药Zevalin（ibritumomab tiuxetan）获FDA批准用于非何杰金氏淋巴瘤 - 诺本专科新特药房  http://www.nbdyf.com/zhongliuke/61.html  Ibritumomab Tiuxetan - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/ibritumomabtiuxetan
 +
#Rituximab（利妥昔单抗），靶点CD20，中国已经上市，Rituximab - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/rituximab
 +
#Tositumomab（托西莫单抗）,靶点CD20，Tositumomab and Iodine I 131 Tositumomab - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/tositumomab-I131tositumomab
 +
#Obinutuzumab（奥滨尤妥珠单抗），靶点CD20，Obinutuzumab - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/obinutuzumab GAZYVA(obinutuzumab 中文名：奥滨尤妥珠单抗)注射剂_海得康海外新特药  http://www.headkonmed.com/headkonmed/products/2923118.html
 +
#Brentuximab vedotin（本妥昔单抗），靶点CD30，Brentuximab Vedotin - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/brentuximabvedotin
 +
#Romidepsin（罗米地辛），靶点HDAC，Romidepsin - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/romidepsin
 +
#Vorinostat（伏立诺他），靶点HDAC，Vorinostat - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/vorinostat
 +
#Belinostat，靶点HDAC，Belinostat - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/belinostat
 +
#Idelalisib，靶点PI3Kδ，Idelalisib - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/idelalisib
 +
#Nivolumab（纳武单抗），靶点PD-1，Nivolumab - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab
 +
#Pembrolizumab（派姆单抗），靶点PD-1，Pembrolizumab - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab
 +
#Bortezomib（硼替佐米），靶点Proteasome，中国已经上市 Bortezomib - National Cancer Institute  https://www.cancer.gov/about-cancer/treatment/drugs/bortezomib
 +
</div>

2017年9月30日 (六) 08:04的最新版本

  1. 史上最全癌症靶向药（2017版） https://mp.weixin.qq.com/s/7mpVHYy4QV8DZZFrU5Nc8w
  2. Overview of Targeted Therapies for Cancer - My Cancer Genome https://www.mycancergenome.org/content/molecular-medicine/overview-of-targeted-therapies-for-cancer
  3. New FDA Approved Drugs for 2017 | CenterWatch http://www.centerwatch.com/drug-information/fda-approved-drugs/
  4. A to Z List of Cancer Drugs - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs

淋巴瘤

  1. Ibrutinib（依鲁替尼），靶点BTK，Ibrutinib (PCI-32765) | BTK 抑制剂 http://www.selleck.cn/products/pci-32765.html Ibrutinib - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/ibrutinib
  2. Ibritumomab tiuxetan（替伊莫单抗），靶点CD20，抗癌新药Zevalin（ibritumomab tiuxetan）获FDA批准用于非何杰金氏淋巴瘤 - 诺本专科新特药房 http://www.nbdyf.com/zhongliuke/61.html Ibritumomab Tiuxetan - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/ibritumomabtiuxetan
  3. Rituximab（利妥昔单抗），靶点CD20，中国已经上市，Rituximab - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/rituximab
  4. Tositumomab（托西莫单抗）,靶点CD20，Tositumomab and Iodine I 131 Tositumomab - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/tositumomab-I131tositumomab
  5. Obinutuzumab（奥滨尤妥珠单抗），靶点CD20，Obinutuzumab - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/obinutuzumab GAZYVA(obinutuzumab 中文名：奥滨尤妥珠单抗)注射剂_海得康海外新特药 http://www.headkonmed.com/headkonmed/products/2923118.html
  6. Brentuximab vedotin（本妥昔单抗），靶点CD30，Brentuximab Vedotin - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/brentuximabvedotin
  7. Romidepsin（罗米地辛），靶点HDAC，Romidepsin - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/romidepsin
  8. Vorinostat（伏立诺他），靶点HDAC，Vorinostat - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/vorinostat
  9. Belinostat，靶点HDAC，Belinostat - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/belinostat
  10. Idelalisib，靶点PI3Kδ，Idelalisib - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/idelalisib
  11. Nivolumab（纳武单抗），靶点PD-1，Nivolumab - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab
  12. Pembrolizumab（派姆单抗），靶点PD-1，Pembrolizumab - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab
  13. Bortezomib（硼替佐米），靶点Proteasome，中国已经上市 Bortezomib - National Cancer Institute https://www.cancer.gov/about-cancer/treatment/drugs/bortezomib
取自“http://wiki.ch-chainclinic.com/index.php?title=靶向药行业研究&oldid=11156”